The University of Chicago Header Logo

Connection

Richard Larson to Adolescent

Back to Details
This is a "connection" page, showing publications Richard Larson has written about Adolescent.
Richard Larson
Connection Strength
1.474
Adolescent
  1. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
    View in: PubMed
    Score: 0.069
  2. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013 Dec 01; 119(23):4170-9.
    View in: PubMed
    Score: 0.041
  3. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012 May; 68(5):723-33.
    View in: PubMed
    Score: 0.036
  4. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7.
    View in: PubMed
    Score: 0.033
  5. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008 Apr 15; 111(8):4022-8.
    View in: PubMed
    Score: 0.028
  6. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15; 109(12):5136-42.
    View in: PubMed
    Score: 0.026
  7. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15; 109(10):4164-7.
    View in: PubMed
    Score: 0.026
  8. Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology). Leukemia. 2025 Dec; 39(12):2926-2934.
    View in: PubMed
    Score: 0.024
  9. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
    View in: PubMed
    Score: 0.023
  10. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005 May 30; 153-154:187-95.
    View in: PubMed
    Score: 0.023
  11. Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study. Cancer. 2025 Feb 15; 131(4):e35750.
    View in: PubMed
    Score: 0.023
  12. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program. 2005; 131-6.
    View in: PubMed
    Score: 0.022
  13. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.021
  14. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 01; 100(7):1438-48.
    View in: PubMed
    Score: 0.021
  15. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.021
  16. The U.S. trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004; 83 Suppl 1:S127-8.
    View in: PubMed
    Score: 0.021
  17. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003 Mar 15; 97(6):1471-80.
    View in: PubMed
    Score: 0.020
  18. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.020
  19. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Adv. 2022 10 11; 6(19):5570-5581.
    View in: PubMed
    Score: 0.019
  20. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022 09 27; 6(18):5345-5355.
    View in: PubMed
    Score: 0.019
  21. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.
    View in: PubMed
    Score: 0.019
  22. Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001 Jul; 38(3 Suppl 6):24-31.
    View in: PubMed
    Score: 0.018
  23. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 06 03; 137(22):3093-3104.
    View in: PubMed
    Score: 0.018
  24. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085.
    View in: PubMed
    Score: 0.017
  25. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.
    View in: PubMed
    Score: 0.017
  26. Children and adolescents in a changing media world. Monogr Soc Res Child Dev. 2001; 66(1):148-54.
    View in: PubMed
    Score: 0.017
  27. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 01; 125(23):4181-4192.
    View in: PubMed
    Score: 0.015
  28. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721.
    View in: PubMed
    Score: 0.015
  29. Patients' perspectives on the definition of cure in chronic myeloid leukemia. Leuk Res. 2019 05; 80:40-42.
    View in: PubMed
    Score: 0.015
  30. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.
    View in: PubMed
    Score: 0.015
  31. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542.
    View in: PubMed
    Score: 0.015
  32. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998 Sep 01; 92(5):1556-64.
    View in: PubMed
    Score: 0.014
  33. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018 07 10; 2(13):1522-1531.
    View in: PubMed
    Score: 0.014
  34. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998 May; 12(5):660-5.
    View in: PubMed
    Score: 0.014
  35. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Sep; 20(5):369-74.
    View in: PubMed
    Score: 0.014
  36. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 08 03; 377(5):454-464.
    View in: PubMed
    Score: 0.013
  37. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 03 09; 376(10):917-927.
    View in: PubMed
    Score: 0.013
  38. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
    View in: PubMed
    Score: 0.013
  39. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395.
    View in: PubMed
    Score: 0.013
  40. Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol. 2016; 136(4):210-218.
    View in: PubMed
    Score: 0.013
  41. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39.
    View in: PubMed
    Score: 0.013
  42. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103.
    View in: PubMed
    Score: 0.013
  43. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016 07 15; 122(14):2178-85.
    View in: PubMed
    Score: 0.012
  44. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279.
    View in: PubMed
    Score: 0.012
  45. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.012
  46. The capacity to be alone as a stress buffer. J Soc Psychol. 1996 Feb; 136(1):5-16.
    View in: PubMed
    Score: 0.012
  47. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15; 85(8):2025-37.
    View in: PubMed
    Score: 0.011
  48. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995 Mar; 9(3):433-9.
    View in: PubMed
    Score: 0.011
  49. Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature. Gynecol Oncol. 1995 Feb; 56(2):307-11.
    View in: PubMed
    Score: 0.011
  50. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant. 2015 Mar; 21(3):559-64.
    View in: PubMed
    Score: 0.011
  51. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan; 16(1):57-66.
    View in: PubMed
    Score: 0.011
  52. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32.
    View in: PubMed
    Score: 0.011
  53. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60.
    View in: PubMed
    Score: 0.010
  54. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 2013 Jan 10; 121(2):385-91.
    View in: PubMed
    Score: 0.010
  55. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood. 1992 Nov 15; 80(10):2463-70.
    View in: PubMed
    Score: 0.010
  56. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. Leukemia. 2013 Jun; 27(6):1411-3.
    View in: PubMed
    Score: 0.010
  57. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study. Br J Haematol. 1992 Oct; 82(2):337-46.
    View in: PubMed
    Score: 0.010
  58. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012 Dec 20; 30(36):4515-23.
    View in: PubMed
    Score: 0.010
  59. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
    View in: PubMed
    Score: 0.009
  60. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012 Sep 01; 30(25):3109-18.
    View in: PubMed
    Score: 0.009
  61. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
    View in: PubMed
    Score: 0.009
  62. Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108.
    View in: PubMed
    Score: 0.009
  63. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.
    View in: PubMed
    Score: 0.009
  64. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7.
    View in: PubMed
    Score: 0.009
  65. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012 Mar 01; 30(7):742-50.
    View in: PubMed
    Score: 0.009
  66. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012 Mar 08; 119(10):2314-24.
    View in: PubMed
    Score: 0.009
  67. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May; 26(5):959-62.
    View in: PubMed
    Score: 0.009
  68. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica. 2011 Oct; 96(10):1488-95.
    View in: PubMed
    Score: 0.009
  69. Daily companionship in late childhood and early adolescence: changing developmental contexts. Child Dev. 1991 Apr; 62(2):284-300.
    View in: PubMed
    Score: 0.009
  70. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011 Apr 01; 29(10):1373-81.
    View in: PubMed
    Score: 0.009
  71. Circulating immune complexes correlate with remission duration in acute myeloid leukemia. Leukemia. 1991 Feb; 5(2):131-7.
    View in: PubMed
    Score: 0.009
  72. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 Dec 20; 28(36):5257-64.
    View in: PubMed
    Score: 0.008
  73. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010 Dec 16; 116(25):5650-9.
    View in: PubMed
    Score: 0.008
  74. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11; 116(19):3758-65.
    View in: PubMed
    Score: 0.008
  75. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9.
    View in: PubMed
    Score: 0.008
  76. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
    View in: PubMed
    Score: 0.008
  77. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Aug 05; 116(5):788-92.
    View in: PubMed
    Score: 0.008
  78. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View in: PubMed
    Score: 0.008
  79. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.008
  80. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21; 115(3):453-74.
    View in: PubMed
    Score: 0.008
  81. Daily emotional states as reported by children and adolescents. Child Dev. 1989 Oct; 60(5):1250-60.
    View in: PubMed
    Score: 0.008
  82. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009 Jul 01; 27(19):3198-204.
    View in: PubMed
    Score: 0.008
  83. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 2009 May 28; 113(22):5575-82.
    View in: PubMed
    Score: 0.008
  84. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008 Nov 01; 26(31):5078-87.
    View in: PubMed
    Score: 0.007
  85. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008 Nov 15; 112(10):4193-201.
    View in: PubMed
    Score: 0.007
  86. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008 Oct 01; 26(28):4603-9.
    View in: PubMed
    Score: 0.007
  87. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54.
    View in: PubMed
    Score: 0.007
  88. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.007
  89. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 01; 110(7):2309-15.
    View in: PubMed
    Score: 0.007
  90. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007 Jun 15; 109(12):5164-7.
    View in: PubMed
    Score: 0.007
  91. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 2006 Jul; 20(7):1295-7.
    View in: PubMed
    Score: 0.006
  92. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
    View in: PubMed
    Score: 0.006
  93. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res. 2005 Nov 15; 11(22):8089-96.
    View in: PubMed
    Score: 0.006
  94. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234-42.
    View in: PubMed
    Score: 0.006
  95. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.006
  96. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 01; 105(9):3420-7.
    View in: PubMed
    Score: 0.006
  97. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
    View in: PubMed
    Score: 0.006
  98. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301.
    View in: PubMed
    Score: 0.006
  99. Alcohol and marijuana use in adolescents' daily lives: a random sample of experiences. Int J Addict. 1984 Jul; 19(4):367-81.
    View in: PubMed
    Score: 0.005
  100. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol. 2004 Jul; 25(1):143-51.
    View in: PubMed
    Score: 0.005
  101. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004 Jun 15; 22(12):2410-8.
    View in: PubMed
    Score: 0.005
  102. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984 May; 76(5):827-41.
    View in: PubMed
    Score: 0.005
  103. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
    View in: PubMed
    Score: 0.005
  104. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer. 2004 Mar; 39(3):217-23.
    View in: PubMed
    Score: 0.005
  105. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
    View in: PubMed
    Score: 0.005
  106. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003 Jun 01; 21(11):2138-46.
    View in: PubMed
    Score: 0.005
  107. Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet. 2003 Jul; 113(1):80-91.
    View in: PubMed
    Score: 0.005
  108. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11):994-1004.
    View in: PubMed
    Score: 0.005
  109. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003 Mar; 17(3):499-514.
    View in: PubMed
    Score: 0.005
  110. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51.
    View in: PubMed
    Score: 0.005
  111. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002 Apr; 33(4):395-400.
    View in: PubMed
    Score: 0.005
  112. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001 Jun 01; 97(11):3574-80.
    View in: PubMed
    Score: 0.004
  113. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
    View in: PubMed
    Score: 0.004
  114. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999 Jun 01; 93(11):3931-9.
    View in: PubMed
    Score: 0.004
  115. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999 Jun 01; 93(11):3983-93.
    View in: PubMed
    Score: 0.004
  116. A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer. Cancer. 1999 Apr 15; 85(8):1843-8.
    View in: PubMed
    Score: 0.004
  117. High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):391-6.
    View in: PubMed
    Score: 0.003
  118. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. Genes Chromosomes Cancer. 1997 Nov; 20(3):282-91.
    View in: PubMed
    Score: 0.003
  119. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia. 1996 May; 10(5):795-802.
    View in: PubMed
    Score: 0.003
  120. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995 Apr; 9(4):628-33.
    View in: PubMed
    Score: 0.003
  121. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22.
    View in: PubMed
    Score: 0.003
  122. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood. 1992 Dec 15; 80(12):2983-90.
    View in: PubMed
    Score: 0.002
  123. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992 Dec 01; 80(11):2873-82.
    View in: PubMed
    Score: 0.002
  124. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transplant. 1992 Jan; 9(1):41-7.
    View in: PubMed
    Score: 0.002
  125. Complex rearrangement of the T cell receptor in large granular lymphocytosis associated with myeloid suppression. Leukemia. 1990 Dec; 4(12):863-5.
    View in: PubMed
    Score: 0.002
  126. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol. 1990 Jul; 75(3):340-5.
    View in: PubMed
    Score: 0.002
  127. Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med. 1990 Jan 11; 322(2):77-82.
    View in: PubMed
    Score: 0.002
  128. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia. 1989 Dec; 3(12):866-70.
    View in: PubMed
    Score: 0.002
  129. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia. 1989 Jan; 3(1):42-7.
    View in: PubMed
    Score: 0.002
  130. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia. 1988 Feb; 2(2):79-83.
    View in: PubMed
    Score: 0.002
  131. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 1986 Jun; 67(6):1765-72.
    View in: PubMed
    Score: 0.002
  132. A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). Am J Clin Pathol. 1984 Jun; 81(6):733-41.
    View in: PubMed
    Score: 0.001
  133. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med. 1983 Sep 15; 309(11):630-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.